ABT vs MDT
Abbott Laboratories and Medtronic, both Healthcare
Abbott Laboratories is the larger company at $154B against $102B. On trailing earnings MDT is the cheaper of the two at a P/E of 24.6 against 31.9, a gap that is only a bargain if the two are growing at similar rates. Over the past year MDT returned +5.4% against -11% for ABT. Ryufin's sector-relative Smart Score puts MDT ahead, 8/10 against 7/10.
| Figure | ABT | MDT |
|---|---|---|
| Last close | $114 | $92.01 |
| Market cap | $154B | $102B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 31.9 | 24.6 |
| Dividend yield | 2.1% | 3.1% |
| 1-year return | -11% | +5.4% |
| 5-year return | +3.2% | -19% |
| Ryufin Smart Scoresector-relative, 1–10 | 7/10 | 8/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Abbott Laboratories
Revenue of $11B in Q1 2026, net income $1.1B. Its largest reported line is Nutritional Products, 41% of the disclosed total.
Medtronic
Revenue of $9.8B in Q4 2026, net income $1.2B. Its largest reported line is Total Other Countries Excluding Ireland, 100% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.